These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3860127)

  • 1. Current therapy and new approaches to the treatment of thalassemia major.
    Wolfe L; Sallan D; Nathan DG
    Ann N Y Acad Sci; 1985; 445():248-55. PubMed ID: 3860127
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of iron overload in Cooley's anemia.
    Cohen A; Mizanin J; Schwartz E
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract]   [Full Text] [Related]  

  • 4. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S
    J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.
    Cohen A; Schwartz E
    Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy.
    Ropars C; Teisseire B; Avenard G; Chassaigne M; Hurel C; Girot R; Nicolau C
    Ann N Y Acad Sci; 1985; 445():304-15. PubMed ID: 3860134
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 10. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
    Piomelli S; Graziano J; Karpatkin M; Dudell GG; Hart D; Hilgartner M; Khanna K; Valdes-Cruz LM; Vora S
    Ann N Y Acad Sci; 1980; 344():409-17. PubMed ID: 6930881
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 12. Deferoxamine-induced growth retardation in patients with thalassemia major.
    De Virgiliis S; Congia M; Frau F; Argiolu F; Diana G; Cucca F; Varsi A; Sanna G; Podda G; Fodde M
    J Pediatr; 1988 Oct; 113(4):661-9. PubMed ID: 3171791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of myocardial and hepatic iron loading by MRI T2* in multi-transfused patients with repeated blood loss as compared to thalassaemia major patients and controls.
    Mavrogeni S
    Blood Transfus; 2011 Jul; 9(3):343-5. PubMed ID: 21627929
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current treatment of thalassemia major in children].
    Lévy G; Bost M
    Pediatrie; 1980; 35(5):451-5. PubMed ID: 7422454
    [No Abstract]   [Full Text] [Related]  

  • 18. Iron overload: pathogenesis and treatment with chelating agents.
    Huebers H
    Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476
    [No Abstract]   [Full Text] [Related]  

  • 19. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW; Winchester P; Giardina PJ; Cunningham-Rundles S
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.